Naarden-based life sciences specialist reaches approximately €7.5 billion in assets under management
DutchNews.nl’s article “Forbion raises €2.3bn, now Europe’s top biotech investor” reports on Forbion’s largest fundraising to date, comprising €2.3 billion for two new biotech funds. The raise brings the firm’s assets under management to approximately €7.5 billion and, based on Preqin data, makes Forbion Europe’s largest dedicated life sciences venture capital firm by assets under management. The article also notes that the fundraising ranks among the largest in global life sciences venture capital over the past five years.
The coverage explains that the funds will finance around 30 companies across the biotech development spectrum, from early-stage ventures to businesses already evaluating potential treatments in patients. Investments will span Europe and North America, supported by backers including Dutch pension managers MN and PGGM and Eli Lilly and Company. DutchNews.nl also places the announcement within the Netherlands’ wider strategic focus on life sciences and biotechnology as priority sectors for attracting highly skilled international talent.